'Once-yearly' exenatide development alliance formed
This article was originally published in Scrip
Executive Summary
Intarcia Therapeutics has entered into an agreement with the contract research organisation Quintiles to accelerate the Phase III development of ITCA 650, for the treatment of type 2 diabetes treatment. ITCA 650 comprises Intarcia's Duros delivery device, which provides continuous subcutaneous delivery of exenatide. The company claims its technology can deliver continuous and consistent drug therapy for up to a full year of therapy from a single ITCA 650 placement.